Table 5.
Clastogenicity study upon long term exposure (36 h) of NR-INF-02 in the absence of metabolic activation in human blood lymphocytes.
| Treatment | Vehicle control |
Positive control MMC (0.20 µg/mL) |
NR-INF-02 (2500.00 µg/mL) |
NR-INF-02 (791.14 µg/mL) |
NR-INF-02 (250.36 µg/mL) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| R1 | R2 | R1 | R2 | R1 | R2 | R1 | R2 | R1 | R2 | |
| Total number of metaphase analyzed | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Normal | 98 | 99 | 89 | 95 | 97 | 99 | 96 | 100 | 100 | 100 |
| Chromatid break | — | — | 4 | 2 | — | — | 1 | — | — | — |
| Chromosome break | — | — | — | — | — | — | — | — | — | — |
| Deletion | — | — | 4 | 3 | 1 | — | — | — | — | — |
| Ring | 1 | 1 | 1 | — | 1 | 1 | 1 | — | — | — |
| Dicentric | — | — | 1 | — | — | — | 2 | — | — | — |
| Fragment | — | — | — | — | 1 | — | — | — | — | — |
| Gap | — | — | — | — | — | — | — | — | — | — |
| Ploidy | 1 | — | 1 | — | — | — | — | — | — | — |
| Endoreduplication | — | — | — | — | — | — | — | — | — | — |
| Total aberrations | 1 | 1 | 10 | 5 | 2 | 1 | 4 | 0 | 0 | 0 |
| Total aberrations (Mean ± SD) | 1.00 ± 0.00 | 7.50 ± 3.53* | 1.50 ± 0.70 | 2.00 ± 2.82 | 0.00 ± 0.00 | |||||
| Mitotic Index (Mean ± SD) | 3.41 ± 0.41 | 2.15 ± 0.07* | 2.86 ± 0.23 | 2.85 ± 0.28 | 3.01 ± 0.01 | |||||
R: replicate; *P < 0.05; MMC: mitomycin C; Ploidy, endoreduplication, gaps, and fragments are not considered as aberrations for calculations.